TNF-α

Lenalidomide is a derivative of thalidomide. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of the micro environment support for tumor cells, and immunomodulatory role. It induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.

Pomalidomide is a derivative of thalidomide and acts as an immunomodulator.

Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.

Necrostatin-1 is an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM).

GW4869 is a cell permeable, selective inhibitor of N-SMase (neutral sphingomyelinase).

C87 is a novel small-molecule TNFα inhibitor; potently inhibits TNFα-induced cytotoxicity with an IC50 of 8.73 μM.

QNZ inhibits the activation of the transcription factor NF-κB and has been used to investigate NF-κB signaling.

Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.

Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.

Necrostatin 2 is a potent necroptosis inhibitor with EC50 of 50 nM.

Ro 08-2750 is a potent and selective Nerve growth factor (NGF) inhibitor that binds the NGF dimer (KD ~ 1 μM).

AX-024 is an orally available inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation (IC50 value 1 nM). Inhibiting an immediate TCR signal has promise for treating a broad spectrum of human T cell-mediated autoimmune and inflammatory diseases.

C25-140, a first-in-class, fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity.

DRI-C21045 is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 ?M.

CPI-1189 (REN 1654, REN 1189) is the proapoptotic cytokine tumor necrosis factor (TNF) alpha inhibitor.

LASSBio-1135 is a dual TRPV1 antagonist and TNF-alpha production inhibitor.